University of California San Francisco

Rita Mukhtar MD
Rita Mukhtar, MD

Associate Professor of Surgery
Division of Surgical Oncology
Lobular Breast Cancer Research Program

Address

550 16th Street, #6311
San Francisco, CA 94158
United States

Biography

Dr. Rita Mukhtar specializes in breast surgery and general surgery for urgent conditions. For her patients with breast cancer, she offers expertise in total skin-sparing mastectomies, breast conservation, wire localization surgery (used to show the location of tissue requiring biopsy) and sentinel lymph node biopsy (used to see if cancer has spread).

Dr. Mukhtar's research program focuses on invasive lobular carcinoma, the second most common type of breast cancer. This work is funded by the American Cancer Society and the National Cancer Institute. She teaches medical students and residents, and serves as an Associate Program Director for the UCSF General Surgery Residency.

Education

Institution Degree Dept or School End Date
University of California Diversity, Equity, and Inclusion Champion Training 2018
University of California, San Francisco M.D. Medicine 2006

Board Certifications

American Board of Surgery, General Surgery

Clinical Expertise

Breast Surgery

Lumpectomy

Seed and wire localization surgery

Nipple sparing/total skin sparing mastectomy

Sentinel lymph node biopsy

Axillary dissection

Emergency General Surgery

Clinical Trials

  1. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles (NCT03053193)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  2. Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) (NCT05964504)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  3. Endocrine Response in Women With Invasive Lobular Breast Cancer (NCT02206984)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  4. Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ (NCT00290745)
    Related Conditions: Breast Cancer, Carcinoma| Start Date: | End Date:

Program Affiliations

Carol Franc Buck Breast Care Center

Research Pathways

Clinical Discovery & Health Services Research

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 162
  1. Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
    Alexandra Thomas, Denise M. Wolf, Ronald Balassanian, Yunn-Yi Chen, Julia Ye, Poonam Vohra, Evin H. Gulbahce, Alexander D. Borowsky, Lamorna Brown Swigart, Gillian L. Hirst, Sara Venters, Rita Nanda, Rebecca Arielle Shatsky, Ralph D'Agostino, Rita A. Mukhtar, Sarah Hatcher, Christina Yau, Angela DeMichele, Laura van 't Veer, Laura Esserman| | View in PubMed
  2. Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer.
    Tchou J, Gottipati S, Goldbach M, Baxter M, Venters S, Balassanian R, Vohra P, Gonzalves D, Ahmad Z, Nayak A, Boughey JC, Mukhtar RA, Chen YY| | View in PubMed
  3. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A| | View in PubMed
  4. ASO Visual Abstract: Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy-Results from the I-SPY2 Clinical Trial.
    Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, ISPY2 Locoregional Working Group, Boughey JC| | View in PubMed
  5. ASO Visual Abstract: Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast-Method of Local Recurrence Detection After Breast Conserving Surgery.
    Clelland EN, Quirarte A, Rothschild HT, Kaur M, Mujir F, Record H, Wong JM, Mukhtar RA| | View in PubMed
  6. ASO Author Reflections: Evolving Paradigms in Axillary Management for Breast Cancer: Insights from the ISPY-2 Neoadjuvant Chemotherapy Trial.
    Switalla KM, Boughey JC, Mukhtar RA| | View in PubMed
  7. ASO Author Reflections: Detecting Local Recurrence After Primary Treatment for Invasive Lobular Carcinoma of the Breast.
    Clelland EN, Mukhtar RA| | View in PubMed
  8. International survey on invasive lobular breast cancer identifies priority research questions.
    Oesterreich S, Pate L, Lee AV, Chen F, Jankowitz RC, Mukhtar R, Metzger O, Sikora MJ, Li CI, Sotiriou C, Shah OS, Koorman T, Ulaner G, Reis-Filho JS, Davidson NM, Van Baelen K, Hutcheson L, Freeney S, Migyanka F, Turner C, Derksen P, Bear T, Desmedt C| | View in PubMed
  9. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
    Switalla KM, Boughey JC, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait LM, Piltin M, Reyna CR, Matsen CB, Tuttle TM, Wallace AM, Arciero CA, Lee MC, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman LJ, Mukhtar RA| | View in PubMed
  10. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.
    Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, , ISPY2 Locoregional Working Group| | View in PubMed
  11. Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery.
    Clelland EN, Quirarte A, Rothschild HT, Kaur M, Mujir F, Record H, Wong JM, Mukhtar RA| | View in PubMed
  12. ASO Visual Abstract: Oncologic Safety of Immediate Oncoplastic Surgery Compared to Standard Breast Conserving Surgery for Patients with Invasive Lobular Carcinoma.
    Falade I, Switalla K, Quirarte A, Baxter M, Soroudi D, Rothschild H, Abe SE, Goodwin K, Piper M, Wong J, Foster R, Mukhtar RA| | View in PubMed
  13. Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
    Erin Frances Cobain, Lajos Pusztai, Cathy Lynne Graham, Pat W. Whitworth, Peter D. Beitsch, Cynthia R. C. Osborne, Rakhshanda Layeequr Rahman, Nathalie MCDOWELL Johnson, Adam Brufsky, Reshma L. Mahtani, VK Gadi, Kent Hoskins, Hannah M. Linden, Rita A. Mukhtar, Laura Esserman, Josien Haan, Katie Quinn, Andrea Menicucci, M. William Audeh, Joyce O'Shaughnessy| | View in PubMed
  14. Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
    Roberto Antonio Leon-Ferre, Katrina Dimitroff, Christina Yau, Karthik Giridhar, Rita A. Mukhtar, Gillian L. Hirst, Nola Hylton, W. Fraser Fraser Symmans, Matthew P. Goetz, Laura Esserman, Judy Caroline Boughey| | View in PubMed
  15. The neoadjuvant approach to treatment of breast cancer: Multidisciplinary management to improve outcomes.
    Alison S. Baskin, Laura A. Huppert, Tatiana Kelil, Lisa Singer, Rita A. Mukhtar| | View in PubMed
  16. Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
    Alexandra Thomas, Denise M. Wolf, Ronald Balassanian, Yunn-Yi Chen, Julia Ye, Poonam Vohra, Evin H Gulbahce, Alexander D. Borowsky, Lamorna Brown Swigart, Gillian L. Hirst, Sara Venters, Rita Nanda, Rebecca Arielle Shatsky, Ralph D'Agostino, Rita A. Mukhtar, Sarah Hatcher, Christina Yau, Angela DeMichele, Laura van 't Veer, Laura Esserman| | View in PubMed
  17. I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
    Amy Jo Chien, Rita A. Mukhtar, Karthik Giridhar, Olufunmilayo I. Olopade, Kevin Kalinsky, Christos Vaklavas, Anthony D. Elias, Mei Wei, Matthew P. Goetz, Laura van 't Veer, Silver Alkhafaji, Hope S. Rugo, Nan Chen, W. Fraser Fraser Symmans, Alexander D. Borowsky, Lamorna Brown Swigart, Natsuko Onishi, Douglas Yee, Nola Hylton, Laura Esserman| | View in PubMed
  18. Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment.
    Corso G, Fusco N, Guerini-Rocco E, Leonardi MC, Criscitiello C, Zagami P, Nicolò E, Mazzarol G, La Vecchia C, Pesapane F, Zanzottera C, Tarantino P, Petitto S, Bianchi B, Massari G, Boato A, Sibilio A, Polizzi A, Curigliano G, De Scalzi AM, Lauria F, Bonanni B, Marabelli M, Rotili A, Nicosia L, Albini A, Calvello M, Mukhtar RA, Robson ME, Sacchini V, Rennert G, Galimberti V, Veronesi P, Magnoni F| | View in PubMed
  19. ASO Author Reflections: The Oncologic Safety of Immediate Oncoplastic Approaches in Invasive Lobular Carcinoma.
    Falade I, Mukhtar RA| | View in PubMed
  20. Oncologic Safety of Immediate Oncoplastic Surgery Compared with Standard Breast-Conserving Surgery for Patients with Invasive Lobular Carcinoma.
    Falade I, Switalla K, Quirarte A, Baxter M, Soroudi D, Rothschild H, Abe SE, Goodwin K, Piper M, Wong J, Foster R, Mukhtar RA| | View in PubMed
  21. Abstract PO4-02-03: Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub study.
    Rita Mukhtar, Christina Yau, Denise Wolf, Adam Brufsky, Hannah Linden, Natasha Hunter, Reshma Mahtani, Abirami Sivapiragasam, Trevor Feinstein, Fengting Yan, Ian Grady, Priscilla McAuliffe, Michaela Tsai, Joyce O'Shaughnessy, Blanche Mavromatis, Sasha Davis, Josien Haan, William Audeh, Lavanya Samraj| | View in PubMed
  22. Abstract PO5-26-07: Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance.
    Laurie Hutcheson, Janice Axelrod, Tracy Cushing, Colleen Fitzwater, Rinath Jeselsohn, Gitte Joergensen, Maria Karsten, Miranda Kimm, Megan Kruse, Theresa Langdon, Julia Levine, Mason Mitchell-Daniels, Rita Mukhtar, Barbara Neilsen, Shani Paluch-Shimon, Therese Pross| | View in PubMed
  23. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
    Alkhafaji S, Wolf DM, Magbanua MJM, J van 't Veer L, Park JW, Esserman L, Mukhtar RA| | View in PubMed
  24. Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy.
    Nadine Goldhammer, Shruti Warhadpande, Liana Beld, Cristian K. Maldonado Rodas, Allison Lam, Tam Binh Bui, Shoko Emily Abe, Michael Alvarado, Cheryl Ewing, Karen Goodwin, Rita Mukhtar, Jasmine Wong, Lamorna Brown Swigart, Gillian Hirst, Christopher Schwartz, Laura van't Veer, Laura Esserman, Jo Chien, Jennifer M. Rosenbluth| | View in PubMed
  25. Management of Concurrent Malignant Phyllodes Tumor and Invasive Breast Carcinoma.
    Chen JJ, Zhu I, Patel A, Krings G, Chen YY, Yuen F, Mukhtar RA, Melisko M, Singer L, Park CC, Prionas ND| | View in PubMed
  26. Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer risk.
    Northey JJ, Hayward MK, Yui Y, Stashko C, Kai F, Mouw JK, Thakar D, Lakins JN, Ironside AJ, Samson S, Mukhtar RA, Hwang ES, Weaver VM| | View in PubMed
  27. ASO Visual Abstract: Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
    Parmeshwar N, Dugan CL, Barnes LL, Cheng JK, Patterson AK, Miller A, Mukhtar R, Piper M| | View in PubMed
  28. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
    Schwartz CJ, Khorsandi N, Blanco A, Mukhtar RA, Chen YY, Krings G| | View in PubMed
  29. ASO Visual Abstract: Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    Ramalingam K, Clelland E, Rothschild H, Mujir F, Record H, Kaur M, Mukhtar RA| | View in PubMed
  30. Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.
    Record H, Clelland E, Rothschild HT, Kaur M, Chien AJ, Melisko M, Rugo HS, Mujir F, Huppert L, Mukhtar RA| | View in PubMed
  31. Letter to the Editor of Annals of Surgical Oncology concerning "Is Choosing Wisely Wise for Lobular Carcinoma in Patients over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns".
    Mukhtar RA, Huppert L, Ramalingam K| | View in PubMed
  32. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA| | View in PubMed
  33. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study.
    S. Gottipati, H.M. Earl, C. Yau, D.A. Cameron, J. Abraham, L. Hayward, F. Reyal, M. Osdoit, G.S. Sonke, J. Wesseling, J. Boughey, M.P. Goetz, A. DeMichele, L. Pusztai, P. Sharma, M. Martin Jimenez, S. Lopez-Tarruella Cobo, M. Del Monte-Millan, F. Symmans, R. Mukhtar| | View in PubMed
  34. Erratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression - CORRIGENDUM.
    Rothschild HT, Jo Chien A, Jankowitz RC, Magbanua MJ, Mouabbi JA, Shatsky RA, Levine J, Mukhtar RA| | View in PubMed
  35. Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
    Parmeshwar N, Dugan CL, Barnes LL, Cheng JK, Patterson AK, Miller A, Mukhtar R, Piper M| | View in PubMed
  36. ASO Author Reflections: Menopausal Status Does Not Predict Successful Breast Conservation Surgery After Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma.
    Ramalingam K, Mukhtar R| | View in PubMed
  37. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    Ramalingam K, Clelland E, Rothschild H, Mujir F, Record H, Kaur M, Mukhtar RA| | View in PubMed
  38. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
    Kaur M, Patterson A, Molina-Vega J, Rothschild H, Clelland E, Ewing CA, Mujir F, Esserman LJ, Olopade OI, Mukhtar RA| | View in PubMed
  39. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
    Clelland EN, Rothschild HT, Patterson A, Molina-Vega J, Kaur M, Symmans WF, Schwartz CJ, Chien AJ, Benz CC, Mukhtar RA| | View in PubMed
  40. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database.
    Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA| | View in PubMed
  41. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.
    Rothschild HT, Clelland EN, Mujir F, Record H, Wong J, Esserman LJ, Alvarado M, Ewing C, Mukhtar RA| | View in PubMed
  42. ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast.
    Rothschild HT, Mukhtar RA| | View in PubMed
  43. Editorial: Contrast mammography-a promising tool for the pre-operative evaluation of lobular breast cancer.
    Jochelson MS, Mukhtar RA| | View in PubMed
  44. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
    Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar RA| | View in PubMed
  45. Metabolic Positron Emission Tomography in Breast Cancer.
    Cecil K, Huppert L, Mukhtar R, Dibble EH, O'Brien SR, Ulaner GA, Lawhn-Heath C| | View in PubMed
  46. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    Mukhtar RA, Chau H, Woriax H, Piltin M, Ahrendt G, Tchou J, Yu H, Ding Q, Dugan CL, Sheade J, Crown A, Carr M, Wong J, Son J, Yang R, Chan T, Terando A, Alvarado M, Ewing C, Tonneson J, Tamirisa N, Gould R, Singh P, Godellas C, Larson K, Chiba A, Rao R, Sauder C, Postlewait L, Lee MC, Symmans WF, Esserman LJ, Boughey JC, ISPY-2 Locoregional Working Group| | View in PubMed
  47. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
    Mukhtar RA, Yau C, Esserman LJ| | View in PubMed
  48. Time to Surgery in Breast Cancer-Is Faster Always Better?
    Mukhtar RA, Esserman LJ| | View in PubMed
  49. 407 Moving from observational studies to a clinical trial: the impact of obesity and surgical weight loss on breast imaging, tissue, and cancer screening experience: the B-BRITE study.
    Elle N Clelland, Judy Gonzalez-Vargas, Sarah G Palilla, Suneil K Koliwad, Heather I Greenwood, Christopher J Schwartz, Chris C. Benz, Diana L Alba, Rita A Mukhtar| | View in PubMed
  50. 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression.
    Harriet T Rothschild, A Jo Chien, Rachel C Jankowitz, Mark JM Magbanua, Jason A Mouabbi, Rebecca A Shatsky, Julia Levine, Rita A Mukhtar| | View in PubMed
  51. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    Rothschild HT, Clelland E, Patterson A, Molina-Vega J, Kaur M, Symmans WF, Schwartz CJ, Chien AJ, Mukhtar RA| | View in PubMed
  52. Abstract HER2-14: HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    Harriet T. Rothschild, Elle Clelland, Anne Patterson, Julissa Molina-Vega, Mandeep Kaur, Mary Kathryn Abel, W. Fraser Symmans, Christopher J. Schwartz, Rita Mukhtar| | View in PubMed
  53. Abstract P2-03-16: Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    Elle Clelland, Harriet T. Rothschild, Anne Patterson, Julissa Molina-Vega, Mandeep Kaur, Mary Kathryn Abel, W. Fraser Symmans, Jo Chien, Christopher J. Schwartz, Rita Mukhtar| | View in PubMed
  54. Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP).
    Jennifer Rosenbluth, Christopher J. Schwartz, Tam Binh Bui, Shruti Warhadpande, Pravin Phadatare, Sigal Eini, Michael Bruck, Julissa Molina-Vega, Kami Pullakhandam, Nicole Schindler, Lamorna A. Brown Swigart, Christina Yau, Gillian Hirst, Rita Mukhtar, Karthik V. Giridhar, Olufunmilayo I. Olopade, Kevin Kalinsky, Cheryl A. Ewing, Jasmine M. Wong, Michael D. Alvarado, Laura Van’t Veer, Laura J. Esserman, Jo Chien| | View in PubMed
  55. Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas.
    Steffi Oesterreich, Leigh Pate, ADRIAN V. LEE, Rachel C. Jankowitz, Patrick Derksen, Rita Mukhtar, Otto Metzger, Matthew J. Sikora, Christopher Li, Christos Sotiriou, Gary Ulaner, Jorge Reis-Filho, Nancy E Davidson, Karen Van Baelen, Laurie Hutcheson, Siobhan Freeney, Flora Migyanka, Claire Turner, Todd Bear, Christine Desmedt| | View in PubMed
  56. Abstract P6-08-09: Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survival.
    Mandeep Kaur, Anne Patterson, Julissa Molina-Vega, Harriet T. Rothschild, Elle Clelland, Mary Kathryn Abel, Laura J. Esserman, Olufunmilayo I. Olopade, Rita Mukhtar| | View in PubMed
  57. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
    Schwartz CJ, Ruiz J, Bean GR, Sirohi D, Joseph NM, Hosfield EM, Jacobs TW, Mukhtar RA, Chen YY, Krings G| | View in PubMed
  58. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes.
    Barnes LL, Foster R, Mukhtar RA, Esserman LJ, Ewing C, Alvarado M, Wong J, Piper M| | View in PubMed
  59. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ| | View in PubMed
  60. Implementation, evaluation, and modification of a near-peer learning group in graduate surgical education.
    Conroy PC, Mohamedaly S, Karimzada M, Brian R, Im C, Hernandez S, Roman S, Hirose K, Mukhtar R, Kirkwood K, O'Sullivan P, Alseidi A| | View in PubMed
  61. ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study.
    Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA| | View in PubMed
  62. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA| | View in PubMed
  63. Hereditary vs Sporadic Invasive Lobular Carcinoma and Impact of Locoregional Therapy on Disease-Free Survival.
    Alison S Baskin, Anne K Patterson, Amie M Blanco, Julie S Mak, Rita A Mukhtar| | View in PubMed
  64. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
    Goodman K, Abel MK, Lawhn-Heath C, Molina-Vega J, Jones EF, Mukhtar RA| | View in PubMed
  65. See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency.
    Tasce Bongiovanni, Elizabeth Lancaster, Hannah Decker, Rita A. Mukhtar, Marisa Schwab, Jeanette Broering, Patricia O’Sullivan, Kenzo Hirose, Elizabeth Wick| | View in PubMed
  66. The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
    Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA| | View in PubMed
  67. ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype.
    Abel MK, Mukhtar RA| | View in PubMed
  68. Abstract LB021: Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer progression.
    Jason J. Northey, Yoshihiro Yui, Mary-Kate Hayward, Connor Stashko, FuiBoon Kai, Janna Mouw, Dhruv Thakar, Jonathon Lakins, Alastair Ironside, Susan Samson, Rita Mukhtar, E. Shelley Hwang, Valerie Weaver| | View in PubMed
  69. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
    Laura Ann Huppert, Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, Amy Jo Chien, Christina Yau, Denise M. Wolf, Donald A. Berry, Laura van 't Veer, Douglas Yee, Angela DeMichele, Laura Esserman| | View in PubMed
  70. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
    Mukhtar R, Symmans WF, Esserman LJ| | View in PubMed
  71. Emotional Regulation in Surgery: Fostering Well-Being, Performance, and Leadership.
    Greenberg AL, Sullins VF, Donahue TR, Sundaram VM, Saldinger PF, Divino CM, Anton NE, Stefanidis D, Reilly LM, Egan RJ, Beals CKJ, Riall TS, Duh QY, Mukhtar RA, Hirose K, Lebares CC| | View in PubMed
  72. Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can
    A. Jo Chien, Kevin M Kalinsky, Julissa Molina-Vega, Rita Mukhtar, Karthik Giridhar, Olufunmilayo I Olopade, Amrita Basu, Smita M Asare, Paul Henderson, Gillian Hirst, Ruixiao Lu, Ella Jones, Nola Hylton, Lamorna Brown-Swigart, Laura J van 't Veer, Douglas Yee, Ingrid Mayer, Laura J Esserman| | View in PubMed
  73. Abstract P2-02-02: Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer.
    Silver Alkhafaji, Denise Wolf, Mark Magbanua, Laura Van 't Veer, John Park, Laura J. Esserman, Rita A. Mukhtar| | View in PubMed
  74. Abstract P3-02-01: Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma.
    Ella F Jones, Deep K Hathi, Natalia Konovalova, Julissa Molina-Vega, David C Newitt, Courtney Lawhn-Heath, Kimberly M Ray, Bonnie N Joe, Diane Heditsian, Susie Brain, A. Jo Chien, Laura J Esserman, Nola M Hylton, Rita A Mukhtar| | View in PubMed
  75. Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers.
    Ella F. Jones, Deep K. Hathi, Julissa Molina-Vega, David C. Newitt, Courtney Lawhn-Heath, Kimberly M. Ray, Bonnie N. Joe, Diane Heditsian, Susie Brain, Rita A. Mukhtar, A. Jo Chien, Hope S. Rugo, Laura J. Esserman, Nola M. Hylton| | View in PubMed
  76. Abstract P3-03-07: Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL.
    Anika Christofferson, Elissa Price, Rita A Mukhtar, Amrita Basu, Laura Esserman, A Jo Chien| | View in PubMed
  77. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
    Abel MK, Shui AM, Melisko M, Chien AJ, Yoshida EJ, Lancaster EM, Van 't Veer L, Esserman LJ, Mukhtar RA| | View in PubMed
  78. O13 BIOLOGIC VERSUS SYNTHETIC MESH IN VENTRAL HERNIA REPAIR: PARTICIPANT-LEVEL ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS AT ONE YEAR.
    Naila Dhanani, Oscar Olavarria, Kyung Hyun Lee, Charlotte Young, Frank Primus, Rita Mukhtar, Julie Holihan, Mike Liang, Hobart Harris| | View in PubMed
  79. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
    Rothschild HT, Abel MK, Patterson A, Goodman K, Shui A, van Baelen K, Desmedt C, Benz C, Mukhtar RA| | View in PubMed
  80. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
    Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA| | View in PubMed
  81. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
    Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ| | View in PubMed
  82. Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
    Khoury AL, Keane H, Varghese F, Hosseini A, Mukhtar R, Eder SE, Weinstein PR, Esserman LJ| | View in PubMed
  83. Correction to: Applications of 3D printing in breast cancer management.
    Galstyan A, Bunker MJ, Lobo F, Sims R, Inziello J, Stubbs J, Mukhtar R, Kelil T| | View in PubMed
  84. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
    Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar RA| | View in PubMed
  85. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.
    Mary Kathryn Abel, Michelle E. Melisko, Hope S. Rugo, Amy Jo Chien, Italia Diaz, Julia K. Levine, Ann Griffin, Joseph McGuire, Laura Esserman, Hala Borno, Rita A. Mukhtar| | View in PubMed
  86. Early onset, multiple, bilateral fibroadenomas of the breast: a case report.
    Im CJ, Miller A, Balassanian R, Mukhtar RA| | View in PubMed
  87. Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions.
    Rita A. Mukhtar, A. Jo Chien| | View in PubMed
  88. Preventing Recurrence in Clean and Contaminated Hernias Using Biologic Versus Synthetic Mesh in Ventral Hernia Repair: The PRICE Randomized Clinical Trial.
    Harris HW, Primus F, Young C, Carter JT, Lin M, Mukhtar RA, Yeh B, Allen IE, Freise C, Kim E, Sbitany H, Young DM, Hansen S| | View in PubMed
  89. Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.
    Tang A, Cohan CM, Hansen KS, Beattie G, Greenwood HI, Mukhtar RA| | View in PubMed
  90. ASO Author Reflections: Changes in Primary Treatment Strategy for Invasive Lobular Carcinoma Highlight the Need for Better Predictors of Therapy Response.
    Mukhtar RA, Boughey JC| | View in PubMed
  91. Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB).
    Mukhtar RA, Hoskin TL, Habermann EB, Day CN, Boughey JC| | View in PubMed
  92. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
    Abel MK, Greenwood H, Kelil T, Guo R, Brabham C, Hylton N, Wong J, Alvarado M, Ewing C, Esserman LJ, Boughey JC, Mukhtar RA| | View in PubMed
  93. Abstract PD5-01: Magnetic resonance imaging insights from an active surveillance cohort of women with DCIS.
    Heather Greenwood, Rita Freimanis, Case Brabham, Rita Mukhtar, Gillian Hirst, Paul Kim, April Liang, Laura Esserman, Nola Hylton, Amrita Basu| | View in PubMed
  94. Abstract PD6-08: DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy.
    Geraldine Tran, Ella Jones, Wen Li, Kelly Fahrner-Scott, David Newitt, Bonnie Joe, Laura Esserman, Nola Hylton, Rita Mukhtar| | View in PubMed
  95. Abstract PS1-03: Active surveillance for DCIS: Clinical outcomes at 5.6 years mean follow-up.
    Case Brabham, Rita Mukhtar, April Liang, Paul Kim, Gillian Hirst, Amrita Basu, Heather Greenwood, Rita Freimanis, Alexander Borowsky, Shelley Hwang, Rick Baehner, Gregor Krings, Nola Hylton, Laura Esserman| | View in PubMed
  96. Abstract PS17-05: Relationship between body mass index and tumor subtype by menopausal status: An analysis in women with lobular carcinoma of the breast.
    Harriet Rothschild, Laura Esserman, Christopher Benz, Rita Mukhtar| | View in PubMed
  97. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
    Scheepens JCC, Veer LV', Esserman L, Belkora J, Mukhtar RA| | View in PubMed
  98. Applications of 3D printing in breast cancer management.
    Galstyan A, Bunker MJ, Lobo F, Sims R, Inziello J, Stubbs J, Mukhtar R, Kelil T| | View in PubMed
  99. A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines.
    Hansen KS, Ghersin H, Piper M, Tavakol M, Lee B, Esserman LJ, Roberts JP, Freise C, Ascher NL, Mukhtar RA| | View in PubMed
  100. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives.
    Mukhtar RA, Brabham CE, Guo R, Abel MK, Wong J, Ewing C, Esserman LJ, Alvarado M| | View in PubMed
  101. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.
    Northey JJ, Barrett AS, Acerbi I, Hayward MK, Talamantes S, Dean IS, Mouw JK, Ponik SM, Lakins JN, Huang PJ, Wu J, Shi Q, Samson S, Keely PJ, Mukhtar RA, Liphardt JT, Shepherd JA, Hwang ES, Chen YY, Hansen KC, Littlepage LE, Weaver VM| | View in PubMed
  102. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
    Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar RA| | View in PubMed
  103. 274 Poster Unintended bias in clinical trials: The prevalence of entry criteria that exclude patients with invasive lobular carcinoma from metastatic breast cancer trials.
    M.K. Abel, I. Diaz, J. Levine, L. Pate, E. Viggiano, M. Melisko, R. Mukhtar| | View in PubMed
  104. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast.
    Abel MK, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Park C, Mukhtar RA| | View in PubMed
  105. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.
    Abel MK, Brabham CE, Guo R, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Mukhtar RA| | View in PubMed
  106. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
    Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM| | View in PubMed
  107. 4314 The Impact of Axillary Surgery on Recurrence-Free Survival in Invasive Lobular Carcinoma (ILC) of the Breast.
    Mary Kathryn Reed Abel, Jasmine Wong, Michael Alvarado, Cheryl Ewing, Laura J. Esserman, Catherine Park, Rita A. Mukhtar| | View in PubMed
  108. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.
    Ruby Guo, Case E. Brabham, Kelly Fahrner-Scott, Mary Kathryn Abel, Jasmine Wong, Michael Alvarado, Laura Esserman, Cheryl Ann Ewing, Rita A. Mukhtar| | View in PubMed
  109. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    Mukhtar RA, Krings G, Chen YY, Mamounas ME, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Rugo H| | View in PubMed
  110. Abstract P3-08-16: The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL.
    Marie Osdoit, Christina Yau, W. Fraser Symmans, Judy C. Boughey, Smita M. Asare, Ron Balassanian, Jodi M. Carter, Yunn-Yi Chen, Kimberly Cole, Laila Khazai, Molly Klein, Dina Kokh, Gregor Krings, Sunati Sahoo, Gretchen Ahrendt, Akiko Chiba, Cheryl Ewing, Constantine Godellas, Nora Jaskowiak, Brigid Killelea, Helen Krontiras, Rachael Lancaster, Julie Lang, M. Catherine Lee, Arpana Naik, Roshni Rao, Julia Tchou, Shannon Tierney, Eleni Tousimis, Tod Tuttle, Anne Wallace, Bev Parker, Laura J. Esserman, Rita A. Mukhtar| | View in PubMed
  111. Abstract P4-13-01: Trends in primary management of invasive lobular carcinoma: An analysis of the National Cancer Database (NCDB).
    Rita A Mukhtar, Tanya L. Hoskin, Elizabeth B. Habermann, Judy C. Boughey| | View in PubMed
  112. Abstract P5-08-05: Risk of subsequent events after initial diagnosis of ductal carcinoma in situ - A large multi-center registry study.
    Thomas O'Keefe, Christina Yau, Eliza Jeong, Emma Iaconetti, Paul Kim, Ann Griffin, Joseph McGuire, Rita Mukhtar, Laura Esserman, Olivier Harismendy, Gillian L. Hirst| | View in PubMed
  113. Abstract P6-16-06: Improved early stratification of invasive cancer risk using MRI in a ductal carcinoma in-situ short-term active surveillance cohort treated with neoadjuvant endocrine therapy.
    Paul Kim, Heather I. Greenwood, Rita I. Freimanis, Gillian L Hirst, Megan Fischer-Colbrie, Jessica Gibbs, Nola M Hylton, Christina Yau, Eun-Sil Shelley Hwang, Laura J. Esserman, Rita A Mukhtar| | View in PubMed
  114. Abstract PD9-08: Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast.
    Kelly Fahrner-Scott, Jasmine M Wong, Merisa Piper, Cheryl Ewing, Michael Alvarado, Laura J Esserman, Nola Hylton, Rita A Mukhtar| | View in PubMed
  115. Pragmatic Trials and Approaches to Transforming Care.
    Peter G. Stock, Rita Mukhtar, Hila Ghersin, Allison Stover Fiscalini, Laura Esserman| | View in PubMed
  116. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
    Cao CX, Sharib JM, Blanco AM, Goldberg D, Bracci P, Mukhtar RA, Esserman LJ, Kirkwood KS| | View in PubMed
  117. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
    Piper ML, Wong J, Fahrner-Scott K, Ewing C, Alvarado M, Esserman LJ, Mukhtar RA| | View in PubMed
  118. Editorial: Applying Margin Consensus Guidelines to Invasive Lobular Carcinoma of the Breast.
    Mukhtar RA| | View in PubMed
  119. Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment.
    Greenwood HI, Wong JM, Mukhtar RA, Alvarado MD, Price ER| | View in PubMed
  120. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM| | View in PubMed
  121. Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
    Mukhtar RA, Holland M, Sieber DA, Wen KW, Rugo HS, Kadin ME, Bean GR| | View in PubMed
  122. Abstract 118: The Impact of Post-Operative Prophylactic Antibiotics in Immediate 2-Stage Prepectoral Breast Reconstruction.
    Michael Holland, Rachel Lentz, Clara Gomez-Sanchez, Jami Rothman, Jasmine Wong, Rita Mukhtar, Hani Sbitany| | View in PubMed
  123. Changes in mammographic density following bariatric surgery.
    Hosseini A, Khoury AL, Varghese F, Carter J, Wong JM, Mukhtar RA| | View in PubMed
  124. Abstract P1-15-15: Accuracy of MRI after neoadjuvant therapy for invasive lobular carcinoma of the breast.
    KE Fahrner-Scott, JM Wong, M Piper, C Ewing, M Alvarado, LJ Esserman, N Hylton, RA Mukhtar| | View in PubMed
  125. Abstract P4-11-01: A simple intervention for long-term relief of chronic post mastectomy pain.
    HJ Keane, AL Khoury, A Hosseini, FP Varghese, R Mukhtar, SE Eder, J Wong, LJ Esserman| | View in PubMed
  126. Abstract P6-01-04: Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    EF Jones, KM Ray, R Mukhtar, W Li, BL Franc, LJ Esserman, BN Joe, MH Pampaloni, NM Hylton| | View in PubMed
  127. Abstract PD7-06: Molecular subtypes of invasive lobular breast cancer in the I-SPY2 TRIAL.
    Z Zhu, C Yau, AJ Chien, T Haddad, LJ Esserman, L van't Veer, RA Mukhtar| | View in PubMed
  128. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, I-SPY2 Investigators| | View in PubMed
  129. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.
    Tang V, Zhao S, Boscardin J, Sudore R, Covinsky K, Walter LC, Esserman L, Mukhtar R, Finlayson E| | View in PubMed
  130. ASO Author Reflections: Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    Mukhtar RA| | View in PubMed
  131. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, and I-SPY 2 Investigators| | View in PubMed
  132. Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    Mukhtar RA, Wong J, Piper M, Zhu Z, Fahrner-Scott K, Mamounas M, Sbitany H, Alvarado M, Foster R, Ewing C, Esserman L| | View in PubMed
  133. 452 (PB-085) The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast.
    M. Mamounas, J. Wong, K. Fahrner-Scott, Y.Y. Chen, G. Krings, C. Ewing, L. Esserman, M. Alvarado, H. Rugo, R. Mukhtar| | View in PubMed
  134. Abstract P2-12-16: The use of oncoplastic surgical techniques to increase successful breast conservation in invasive lobular carcinoma of the breast.
    JM Wong, ML Piper, C Ewing, M Alvarado, LJ Esserman, H Sbitany, RD Foster, RA Mukhtar| | View in PubMed
  135. Abstract P5-12-04: The impact of bariatric surgery on mammographic breast density.
    A Hosseini, AL Khoury, J Carter, JM Wong, MD Alvarado, C Ewing, LJ Esserman, RA Mukhtar| | View in PubMed
  136. Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention.
    A Hosseini, LJ Esserman, AM Wallace, A Au, RA Mukhtar| | View in PubMed
  137. Breast tumor location in BRCA mutation carriers and implications for prevention.
    Ava Hosseini, Laura Esserman, Anne M. Wallace, Amal Khoury, Alfred Au, Rita Mukhtar| | View in PubMed
  138. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L| | View in PubMed
  139. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.
    Mukhtar RA, Piper ML, Freise C, Van't Veer LJ, Baehner FL, Esserman LJ| | View in PubMed
  140. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
    Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ| | View in PubMed
  141. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
    Mukhtar RA, Wong JM, Esserman LJ| | View in PubMed
  142. Abstract PD1-5: Characterizing the Tumor Immune MicroEnvironment (TIME) in high-risk ductal carcinoma in situ.
    Michael J Campbell, Rita Mukhtar, Ekene Obi-Okoye, Booyeon Han, Vickram Tandon, Sarah Zheng, Zelos Zhu, Max Endicott, Max Wicha, Linda Lindstrom, Alfred Au, Frederick Baehner, Joe Gray, Laura Esserman| | View in PubMed
  143. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ| | View in PubMed
  144. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ| | View in PubMed
  145. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E, I-SPY TRIAL Investigators| | View in PubMed
  146. Biology of breast cancer in Nigerian women: a pilot study.
    Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ| | View in PubMed
  147. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ| | View in PubMed
  148. P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial.
    RA Mukhtar, E Lips, J Wesseling, C Livasy, C Yau, D Berry, L van't Veer, LA Carey, LJ Esserman, S Rodenhuis, ES Hwang| | View in PubMed
  149. P4-09-19: PCNA+ Tumor Associated Macrophages Are Associated with M1 and M2 Gene Expression, and Confer Poor Prognosis in the Absence of Anti-Tumor Immune Environment.
    R Mukhtar, D Wolf, V Tandon, J Zhu, M Lenburg, Veer L van't, MJ Campbell| | View in PubMed
  150. PD02-05: MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial.
    RA Mukhtar, N Hylton, M Rosen| | View in PubMed
  151. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ| | View in PubMed
  152. Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness.
    R. Mukhtar, A. P. Moore, V. Tandon, O. Nseyo, A. Au, F. L. Baehner, C. A. Adisa, N. Eleweke, O. I. Olopade, D. H. Moore, M. Campbell, L. Esserman| | View in PubMed
  153. Benign Thoracic Disease in the Elderly.
    Rita A. Mukhtar, Pierre R. Theodore| | View in PubMed
  154. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ| | View in PubMed
  155. Abstract P2-09-11: Response of Invasive Lobular Cancers to Neoadjuvant Therapy.
    RA Mukhtar, ES Hwang, C Livasy, LJ. Esserman| | View in PubMed
  156. Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences.
    R. Mukhtar, A. Moore, O. Nseyo, A. Au, F. L. Baehner, D. H. Moore, M. Campbell, L. Esserman| | View in PubMed
  157. Long-term survival and renal transplantation in a monozygotic twin with cloacal dysgenesis sequence.
    Mukhtar RA, Baskin LS, Stock PG, Lee H| | View in PubMed
  158. Bacteriologic features of surgical site infections following breast surgery.
    Mukhtar RA, Throckmorton AD, Alvarado MD, Ewing CA, Esserman LJ, Chiu C, Hwang ES| | View in PubMed
  159. Benign thoracic disease in the elderly.
    Mukhtar RA, Theodore PR| | View in PubMed
  160. Variation in annual volume at a university hospital does not predict mortality for pancreatic resections.
    Mukhtar RA, Kattan OM, Harris HW| | View in PubMed
  161. Image of the month--quiz case. Traumatic intramuscular cyst of the duodenum.
    Spitzer AL, Mukhtar RA, Harris HW| | View in PubMed
  162. Quality-of-life issues in psoriasis.
    Mukhtar R, Choi J, Koo JY| | View in PubMed